Abstract
Purpose
Inhibitors of intestinal alpha-glucosidases are used therapeutically to treat type 2 diabetes mellitus. Bacteria such as Actinoplanes sp. naturally produce potent alpha-glucosidase inhibitor compounds, including the most widely available drug acarbose. It is not known whether lactic acid bacteria (LAB) colonising the human gut possess inhibitory potential against glucosidases. Hence, the study was undertaken to screen LABs having inherent alpha- and beta-glucosidase inhibitory potential.
Methods
This study isolated, screened, identified and extracted Lactobacillus strains (Lb1–15) from human infant faecal samples determining their inhibitory activity against intestinal maltase, sucrase, lactase and amylase. Lactobacillus reference strains (Ref1–7), a Gram positive control (Ctrl1) and two Gram negative controls (Ctrl2–3), were also analysed to compare activity.
Results
Faecal isolates were identified by DNA sequencing, with the majority identified as unique strains of Lactobacillus plantarum. Some strains (L. plantarum, L. fermentum, L. casei and L. rhamnosus) had potent and broad spectrum inhibitory activities (up to 89 %; p < 0.001; 500 mg/ml wet weight) comparable to acarbose (up to 88 %; p < 0.001; 30 mg/ml). Inhibitory activity was concentration-dependent and was freely available in the supernatant, and was not present in other bacterial genera (Bifidobacterium bifidum and Escherichia coli or Salmonella typhimurium). Interestingly, the potency and spectrum of inhibitory activity across strains of a single species (L. plantarum) differed substantially. Some Lactobacillus extracts had broader spectrum activities than acarbose, effectively inhibiting beta-glucosidase activity (lactase) as well as alpha-glucosidase activities (maltase, sucrase and amylase). Anti-diabetic potential was indicated by the fact that oral gavage with a L. rhamnosus extract (1 g/kg) was able to reduce glucose excursions (Area under curve; 22 %; p < 0.05) in rats during a carbohydrate challenge (starch; 2 g/kg).
Conclusion
These results definitively demonstrate that Lactobacillus strains present in the human gut have alpha- and beta-glucosidase inhibitory activities and can reduce blood glucose responses in vivo. Although the potential use of LAB such as Lactobacillus as a dietary supplement, medicinal food or biotherapeutic for diabetes is uncertain, such an approach might offer advantages over drug therapies in terms of broader spectrum activities and fewer unpleasant side effects. Further characterisation of this bioactivity is warranted, and chronic studies should be undertaken in appropriate animal models or diabetic subjects.
Similar content being viewed by others
Abbreviations
- LAB:
-
Lactic acid bacteria
- GRAS:
-
Generally recognised as safe
- SE:
-
Sonicated extract
- SN:
-
Supernatant
References
Sales PM, Souza PM, Simeoni LA, Magalhaes PO, Silveira D (2012) α-Amylase inhibitors: a review of raw material and isolated compounds from plant source. J Pharm Pharm Sci 15(1):141–183
Kazeem MI, Dansu TV, Adeola SA (2013) Inhibitory effect of Azadirachta indica A. Juss leaf extract on the activities of α-amylase and α-glucosidase. Pak J Biol Sci 16(21):1358–1362
Lebovitz HE (1997) Alpha-glucosidase inhibitors. Endocrinol Metab Clin 26(3):539–551
Derosa G, Maffioli P (2012) α-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci 8(5):899–906
Creutzfeldt W (1999) Effects of the α-glucosidase inhibitor acarbose on the development of long term complications in diabetic animals: pathophysiological and therapeutic implications. Diabetes Metab Res Rev 15:289–296
Standl E, Schnell O (2012) Alpha-glucosidase inhibitors 2012—cardio vascular considerations and trial evaluation. Diabetes Vasc Dis Res 9(3):163–169
Chang J, Block TM, Guo JT (2013) Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions. Antivir Res 99(3):251–260
Rosak C, Mertes G (2012) Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. Diabetes Metab Syndr Obes 5:357–367
Derosa G, Maffioli P (2012) Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. Clin Ther 34(6):1221–1236
Tschope D, Hanefeld M, Meier JJ, Gitt AK, Halle M, Bramlage P, Schumm-Draeger PM (2013) The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes. Cardiovasc Diabetol 12:62
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077
Al-Zuhair S, Dowaidar A, Kamal H (2010) Inhibitory effect of dates-extract on α-amylase and β-glucosidase enzymes relevant to non-insulin dependent diabetes mellitus. J Biochem Tech 2(2):158–160
Tundis R, Loizzo MR, Menichini F (2010) Natural products as alpha-amylase and alpha-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: an update. Mini Rev Med Chem 10(4):315–331
Mohamed ELH, Siddiqui MJA, Ang LF, Sadikun A, Chan SH, Tan SC, Asmawi MZ, Yam MF (2012) Potent α-glucosidase and α-amylase inhibitory activities of standardized 50% ethanolic extracts and sinensetin from Orthosiphonstamineus Benth as anti-diabetic mechanism. BMC Complement Altern Med 12:176
Nair SS, Kavrekar V, Mishra A (2013) In vitro studies on alpha amylase and alpha glucosidase inhibitory activities of selected plant extracts. Eur J Exp Biol 3(1):128–132
Katekhaye SD, Nagmoti DM (2013) α-Glucosidase and α-amylase inhibitory activities of Pithecellobium dulce bark and leaves. Phytopharmacology 4(1):123–130
Yamada T, Hida H, Yamada Y (2007) Chemistry, physiological properties, and microbial production of hydroxycitric acid. Appl Microbiol Biotechnol 75(5):977–982
Schwientek P, Szczepanowski R, Ruckert C, Kalinowski J, Klein A, Selber K, Wehmeier UF, Stoye J, Puhler A (2012) The complete genome sequence of theacarbose producer Actinoplanes sp. SE50/110. BMC Genomics 13:112
Ramchandran L, Shah NP (2008) Proteolytic profiles and angiotensin-1 converting enzyme and alpha-glucosidase inhibitory activities of selected lactic acid bacteria. J Food Sci 73(2):M75–M81
Panwar H, Rashmi HM, Batish VK, Grover S (2013) Probiotics as potential biotherapeutics in the management of type 2 diabetes—prospects and perspectives. Diabetes Metab Res Rev 29:103–112
Ritchie ML, Romanuk TN (2012) A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One 7(4):e34938
Chapman TM, Plosker GL, Figgitt DP (2007) Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases. Bio Drugs 21(1):61–63
Anonymous or Sigma Tau Pharmaceuticals Inc. (2011) VSL#3 double strength product information sheet. http://www.vsl3.com/pdf/VSL3_DS_PL.pdf
Dubernet S, Desmasures N, Gueguen M (2002) A PCR based method for identification of lactobacilli at the genus level. FEMS Microbiol Lett 214(2):271–275
Turner S, Pryer KM, Miao VPW, Palmer JD (1999) Investigating deep phylogenetic relationships among cyanobacteria and plastids by small subunit rRNA sequence analysis. J Eukaryot Microbiol 46:327–338
Rogall TJ, Wolters TF, Bottger EC (1990) Towards a phylogeny and definition of species at the molecular level within the genus Mycobacterium. Int J Syst Bacteriol 40:323–330
Naser SM, Dawyndt P, Hoste B, Gevers D, Vandemeulebroecke K, Cleenwerck I, Vancanneyt M, Swings J (2007) Identification of lactobacilli by pheS and rpoA gene sequence analyses. Int J Syst Evol Microbiol 57:2777–2789
Burington RS (1973) Handbook of mathematical tables and formulas. McGraw-Hill, New York
Meng P, Xie C, Geng P, Qi X, Zheng F, Bai F (2013) Inhibitory effect of components from Streptomyces species on alpha-glucosidase and alpha-amylase of different origin. Prikl Biokhim Mikrobiol 49(2):181–189
Onose S, Ikeda R, Nakagawa K, Kimura T, Yamagishi K, Higuchi O, Miyazawa T (2013) Production of the α-glycosidase inhibitor 1-deoxynojirimycin from Bacillus species. Food Chem 138(1):516–523
Chaudet MM, Allen JL, Rose DR (2012) Expression and purification of two Family GH31 α-glucosidases from Bacteroides thetaiotaomicron. Protein Expr Purif 86(2):135–141
Ley RE, Peterson DA, Gordon JI (2006) Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124:837–848
Walter J, Ley R (2011) The human gut microbiome: ecology and recent evolutionary changes. Annu Rev Microbiol 65:411–429
Mountzouris KC, Kotzampassi K, Tsirtsikos P, Kapoutzis K, Fegeros K (2009) Effects of Lactobacillus acidophilus on gut microflora metabolic biomarkers in fed and fasted rats. Clin Nutr 28(3):318–324
Perez-Martín F, Sesena S, Izquierdo PM, Martín R, Palop ML (2012) Screening for glycosidase activities of lactic acid bacteria as a biotechnological tool in oenology. World J Microbiol Biotechnol 28(4):1423–1432
Holt SM, Teresi JM, Cote GL (2008) Influence of alternansucrase-derived oligosaccharides and other carbohydrates on alpha-galactosidase and alpha-glucosidase activity in Bifidobacterium adolescentis. Lett Appl Microbiol 46(1):73–79
Park JE, Park SH, Woo JY, Hwang HS, Cha J, Lee H (2013) Enzymatic properties of a thermostable α-glucosidase from acidothermophilic crenarchaeon Sulfolobus tokodaii strain 7. J Microbiol Biotechnol 23(1):56–63
Acknowledgments
Harsh Panwar was funded by a PhD studentship (INCN-2011-43) from Commonwealth Scholarship Commission, UK to conduct studies at Queen’s University Belfast (UK).
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Panwar, H., Calderwood, D., Grant, I.R. et al. Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential. Eur J Nutr 53, 1465–1474 (2014). https://doi.org/10.1007/s00394-013-0649-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00394-013-0649-9